ET-01
-
Therapeutic Approach
Using gene-editing technology to edit BCL11A erythroid enhancer in hematopoietic stem cells (HSC), ET-01 is an autologous cell therapy being developed to increase the fetal hemoglobin level in red blood cells for severe β-thalassemia patients.
-
Poster Presentation at the 61st ASH Annual Meeting
EdiGene presented the manufacturing scale-up and preclincial development data of ET-01 for the β-thalassemia gene editing treatment at the 61st ASH annual meeting in 2019.
ET-02
-
Therapeutic Approach
Edit immuno-rejection molecules in T cells from healthy donors, leveraging partner’s proprietary CAR-T to create best-in-class U CART process and U CAR-T product.
Follow us on WeChat
Careers : hr@EdiGene.com
Partnership : bd@EdiGene.com
Media Inquiries : media@EdiGene.com